All Press Releases
PILA PHARMA: NEW INTERVIEW ON RIGHTS ISSUE AND BET ON OBESITY WITH DIREKT STUDIOS
Malmö, 07 July 2025 PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, informs investors and others with interest in the space of a new corporate presentation in connection to its ongoing rights issue that will finance a new venture in pure obesity studies. The…
CEO DISCUSSES ONGOING RIGHTS ISSUE AND BET ON OBESITY WITH INVESTMENT PODCAST 10X
Malmö, 04 July 2025 PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, informs investors and others with interest in the space of the participation in a new podcast episode, released today July 4, 2025! Together with Joakim Båge from Swedish investment focused podcast, 10X, CEO…
PILA PHARMA DISCUSSES ITS FINANCING ROUND WITH HELGE LARSEN & PROINVESTOR
Malmö, 01 July 2025 PILA PHARMA AB (publ) (FN STO: PILA) has the pleasure to share with investors and others with interest in the Company or the general market, that PILA PHARMA has had another 1-on-1 interview with Helge Larsen from ProInvestor, conducted 27 June 2025.ProInvestor is Denmark's largest and one of the most sophisticated online forums uniting private and…